Contraindications: Cenforce D 160 is absolutely contraindicated with nitrate medications (including GTN sprays, isosorbide patches, and recreational nitrites such as amyl nitrite) — the combined hypotensive effect can be life-threatening. Men with unstable angina, recent myocardial infarction (within 90 days), stroke (within 6 months), resting hypotension (< 90/50 mmHg), or severe hepatic impairment must not use this product. Alpha-blocker co-administration carries a significant orthostatic hypotension risk, particularly relevant for men using doxazosin or tamsulosin for urological indications.
Side Effects: At the 160 mg dose, vasodilatory effects — including facial warmth, transient visual chromatopsia (blue-green colour tinge documented in 3 % of sildenafil users in Phase III data), and nasal congestion — occur at higher incidence than at 50–100 mg. Exercise further amplifies peripheral blood flow, potentially intensifying these responses. Priapism (erection lasting > 4 hours) requires immediate emergency intervention; irreversible corpus cavernosum damage occurs after 6 hours without decompression.
Monitoring: Blood pressure should be measured before each dose and again post-exercise when combining sildenafil with cardio training. Resting heart rate above 100 bpm on the day of intended use is a reason to defer. Liver function panels (ALT/AST) are recommended every 6–12 months for men using sildenafil at supratherapeutic doses on a frequent schedule. Report any sudden visual or hearing loss immediately — both are rare but serious adverse events associated with PDE5 inhibitor class.
PCT: Sildenafil is not a hormonal compound and does not suppress the hypothalamic-pituitary-gonadal axis; no post-cycle therapy protocol is required following a course of Cenforce D 160. However, men who use sildenafil within anabolic steroid cycles should note that androgenic compounds can independently elevate haematocrit and blood viscosity, which modifies the cardiovascular risk calculation when a PDE5 inhibitor is also present.